We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Verquvo

News List

Merck Announces Initiation of Phase 3 Study Evaluating VERQUVO® in Patients with Chronic Heart Failure and Reduced Ejection Fraction Who Have Not Had a Recent Worsening Heart Failure Event AmericanPharmaceuticalReview
November 12, 2021
Merck announced the initiation of VICTOR (vericiguat in adults with Chronic heart failure and Reduced ejection fraction), a pivotal Phase 3 randomized, placebo-controlled cardiovascular clinical trial...
MSD, Bayer’s heart failure med Verquvo gains EU approval pharmatimes
July 23, 2021
The European Commission (EC) has approved MSD and Bayer’s Verquvo for the treatment of symptomatic chronic heart failure in patients with reduced ejection fraction.
US approval for MSD’s heart failure med Verquvo pharmatimes
January 22, 2021
The Food and Drug Administration (FDA) in the US has approved MSD’s (known as Merck in the US and Canada) heart failure treatment Verquvo (vericiguat).